Avantor Partners with BlueWhale Bio to Accelerate CAR-T Therapy Manufacturing

Avantor, Inc., a global leader in life sciences and advanced technology products, has announced a strategic partnership with BlueWhale Bio, a commercial-stage company focused on revolutionizing immune cell therapy manufacturing. The collaboration aims to address critical bottlenecks in CAR-T therapy production by streamlining manufacturing processes, reducing variability, and shortening time-to-patient.

The partnership will leverage Avantor’s expertise in bioprocessing and custom reagent manufacturing alongside BlueWhale Bio’s Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. Together, they plan to scale up the production of GMP-grade CDNP materials, supporting CAR-T developers in accelerating cell expansion and improving manufacturing capacity.

“CAR-T therapies have transformed cancer care, but manufacturing remains a significant hurdle due to cost, variability, and long release times,” said Emmanuel Ligner, CEO of Avantor. “Our collaboration with BlueWhale Bio integrates next-generation reagents into a scalable platform to help overcome these challenges.”

BlueWhale Bio’s preclinical and clinical data suggest that Synecta™ CDNPs enable earlier cell division, higher yields, and fewer process interventions. Notably, the platform is already in clinical trials employing a 3-day CAR-T manufacturing process.

“By partnering with Avantor, we combine innovative technology with robust manufacturing capabilities to accelerate the journey from discovery to delivery,” said Peter Keller, CEO of BlueWhale Bio.

This collaboration promises to enhance CAR-T manufacturing efficiency and potentially expand patient access to these life-saving therapies.